Dutch device company ViCentra has raised $85m to boost its Kaleido insulin patch pump’s entry onto the US market.
According to the company, initial commercial uptake for the pump in Germany, France, and the Netherlands has driven higher-than-expected demand after a staggered European rollout in 2023.
The latest funding will therefore also support the scale-up of ViCentra’s manufacturing capabilities to meet this demand, along with filing activities with the US Food and Drug Administration (FDA) to support Kaleido’s US market entry.
Related: Berlin Heals Holding raises over $5m to advance heart failure treatment
ViCentra’s Series D funding round was led by new investor Innovation Industries. Existing investors Partners in Equity, Invest-NL, and EQT Life Sciences and Health Innovations also participated.
ViCentra CEO Tom Arnold commented: “With this funding, we can now meet surging European demand and fast-track our entry into the US market.”
The insulin pump market represents a significant growth area. GlobalData analysis forecasts that the global market will reach a valuation of more than $16bn by 2034, up from around $7.5bn in 2024.
In the US, the insulin pump market remains competitive. According to a GlobalData market model, Dexcom held a 20.2% share of the combined insulin pump and continuous glucose monitoring (CGM) market in 2024, followed closely by Abbott and Insulet, with market shares of 17.7% and 15.2%, respectively.
In 2023, ViCentra announced a collaboration with Dexcom and France’s Diabeloop to develop a closed-loop system for insulin delivery. Set to be embedded within ViCentra’s next-generation version of Kaleido, the system uses an algorithm developed by Diabeloop to receive information from Dexcom’s G6/G7 CGM sensors to deliver insulin to patients at the appropriate time. The company anticipates Kaleido 2’s rollout to begin in Europe, initially in France and Germany, in early 2026.
Other companies that have recently made closed-loop system integrations for their insulin pumps include Tandem Diabetes Care. In June, the company announced its t:slim X2 pump’s compatibility with Abbott’s FreeStyle Libre 3 Plus CGM sensor.
According to GlobalData analysis, the diabetes market is increasingly favouring closed-loop technologies that combine extended sensor life, real-time glucose visibility and intelligent insulin dosing – an area where interoperability between devices is becoming a core differentiator.
